These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 23399758)
1. Listeriolysin O as a strong immunogenic molecule for the development of new anti-tumor vaccines. Sun R; Liu Y Hum Vaccin Immunother; 2013 May; 9(5):1058-68. PubMed ID: 23399758 [TBL] [Abstract][Full Text] [Related]
2. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Sewell DA; Shahabi V; Gunn GR; Pan ZK; Dominiecki ME; Paterson Y Cancer Res; 2004 Dec; 64(24):8821-5. PubMed ID: 15604239 [TBL] [Abstract][Full Text] [Related]
3. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. Singh R; Dominiecki ME; Jaffee EM; Paterson Y J Immunol; 2005 Sep; 175(6):3663-73. PubMed ID: 16148111 [TBL] [Abstract][Full Text] [Related]
4. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma. Neeson P; Pan ZK; Paterson Y Cancer Immunol Immunother; 2008 Apr; 57(4):493-505. PubMed ID: 17876582 [TBL] [Abstract][Full Text] [Related]
5. A gold glyco-nanoparticle carrying a Listeriolysin O peptide and formulated with Advax™ delta inulin adjuvant induces robust T-cell protection against listeria infection. Rodriguez-Del Rio E; Marradi M; Calderon-Gonzalez R; Frande-Cabanes E; Penadés S; Petrovsky N; Alvarez-Dominguez C Vaccine; 2015 Mar; 33(12):1465-73. PubMed ID: 25659269 [TBL] [Abstract][Full Text] [Related]
6. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. Gunn GR; Zubair A; Peters C; Pan ZK; Wu TC; Paterson Y J Immunol; 2001 Dec; 167(11):6471-9. PubMed ID: 11714814 [TBL] [Abstract][Full Text] [Related]
7. A listeriolysin O subunit vaccine is protective against Listeria monocytogenes. Phelps CC; Vadia S; Boyaka PN; Varikuti S; Attia Z; Dubey P; Satoskar AR; Tweten R; Seveau S Vaccine; 2020 Aug; 38(36):5803-5813. PubMed ID: 32684498 [TBL] [Abstract][Full Text] [Related]
8. Specific targeting of a pore-forming toxin (listeriolysin O) to LHRH-positive cancer cells using LHRH targeting peptide. Kheirandish MH; Jaliani HZ; Rahmani B; Nikukar H Toxicon; 2019 Jun; 164():82-86. PubMed ID: 30991063 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant properties of listeriolysin O protein in a DNA vaccination strategy. Peng X; Treml J; Paterson Y Cancer Immunol Immunother; 2007 Jun; 56(6):797-806. PubMed ID: 17102978 [TBL] [Abstract][Full Text] [Related]
10. Listeria monocytogenes-derived listeriolysin O has pathogen-associated molecular pattern-like properties independent of its hemolytic ability. Wallecha A; Wood L; Pan ZK; Maciag PC; Shahabi V; Paterson Y Clin Vaccine Immunol; 2013 Jan; 20(1):77-84. PubMed ID: 23136118 [TBL] [Abstract][Full Text] [Related]
11. An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model. Seavey MM; Maciag PC; Al-Rawi N; Sewell D; Paterson Y J Immunol; 2009 May; 182(9):5537-46. PubMed ID: 19380802 [TBL] [Abstract][Full Text] [Related]
12. High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. Kim SH; Castro F; Paterson Y; Gravekamp C Cancer Res; 2009 Jul; 69(14):5860-6. PubMed ID: 19584282 [TBL] [Abstract][Full Text] [Related]
13. Intracytoplasmic delivery of listeriolysin O by a vaccinal strain of Bacillus anthracis induces CD8-mediated protection against Listeria monocytogenes. Sirard JC; Fayolle C; de Chastellier C; Mock M; Leclerc C; Berche P J Immunol; 1997 Nov; 159(9):4435-43. PubMed ID: 9379042 [TBL] [Abstract][Full Text] [Related]
14. Listeriolysin O expressed in a bacterial vaccine suppresses CD4+CD25high regulatory T cell function in vivo. Nitcheu-Tefit J; Dai MS; Critchley-Thorne RJ; Ramirez-Jimenez F; Xu M; Conchon S; Ferry N; Stauss HJ; Vassaux G J Immunol; 2007 Aug; 179(3):1532-41. PubMed ID: 17641019 [TBL] [Abstract][Full Text] [Related]
15. Listeriolysin O immunogenetic adjuvant enhanced potency of hepatitis C virus NS3 DNA vaccine. Pouriayevali MH; Bamdad T; Sadat SM; Sadeghi SA; Sabahi F; Mahdavi M; Aghasadeghi MR IUBMB Life; 2019 Oct; 71(10):1645-1652. PubMed ID: 31298809 [TBL] [Abstract][Full Text] [Related]
16. Antilisterial immunity includes specificity to listeriolysin O (LLO) and non-LLO-derived determinants. Bouwer HG; Gibbins BL; Jones S; Hinrichs DJ Infect Immun; 1994 Mar; 62(3):1039-45. PubMed ID: 7509313 [TBL] [Abstract][Full Text] [Related]
17. Multifaceted activity of listeriolysin O, the cholesterol-dependent cytolysin of Listeria monocytogenes. Seveau S Subcell Biochem; 2014; 80():161-95. PubMed ID: 24798012 [TBL] [Abstract][Full Text] [Related]
18. Development of a Listeria monocytogenes based vaccine against prostate cancer. Shahabi V; Reyes-Reyes M; Wallecha A; Rivera S; Paterson Y; Maciag P Cancer Immunol Immunother; 2008 Sep; 57(9):1301-13. PubMed ID: 18273616 [TBL] [Abstract][Full Text] [Related]
19. Listeriolysin o is strongly immunogenic independently of its cytotoxic activity. Carrero JA; Vivanco-Cid H; Unanue ER PLoS One; 2012; 7(3):e32310. PubMed ID: 22403645 [TBL] [Abstract][Full Text] [Related]
20. A combined use of autolysin p60 and listeriolysin O antigens induces high protective immune responses against Listeria monocytogenes infection. Luo X; Cai X Curr Microbiol; 2012 Dec; 65(6):813-8. PubMed ID: 23001425 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]